RU2005127666A - Малонамидные производные в качестве ингибиторов гамма-секретазы - Google Patents
Малонамидные производные в качестве ингибиторов гамма-секретазы Download PDFInfo
- Publication number
- RU2005127666A RU2005127666A RU2005127666/04A RU2005127666A RU2005127666A RU 2005127666 A RU2005127666 A RU 2005127666A RU 2005127666/04 A RU2005127666/04 A RU 2005127666/04A RU 2005127666 A RU2005127666 A RU 2005127666A RU 2005127666 A RU2005127666 A RU 2005127666A
- Authority
- RU
- Russia
- Prior art keywords
- methyl
- oxo
- malonamide
- compounds
- formula
- Prior art date
Links
- WRIRWRKPLXCTFD-UHFFFAOYSA-N malonamide Chemical class NC(=O)CC(N)=O WRIRWRKPLXCTFD-UHFFFAOYSA-N 0.000 title claims 2
- 239000003540 gamma secretase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 34
- 229910052739 hydrogen Inorganic materials 0.000 claims 23
- 239000001257 hydrogen Substances 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 17
- -1 benzo [b] thiophenyl Chemical group 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 16
- 150000002431 hydrogen Chemical class 0.000 claims 15
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 125000006288 3,5-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(C([H])=C1F)C([H])([H])* 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000006168 tricyclic group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- HXOPUXUYXNWCJU-UHFFFAOYSA-N 2-methyl-n-(5-methyl-6-oxo-7h-benzo[d][1]benzazepin-7-yl)-n'-[(2,3,5-trifluorophenyl)methyl]propanediamide Chemical compound C12=CC=CC=C2C2=CC=CC=C2N(C)C(=O)C1NC(=O)C(C)C(=O)NCC1=CC(F)=CC(F)=C1F HXOPUXUYXNWCJU-UHFFFAOYSA-N 0.000 claims 1
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- VEHTZQNYIWZNBK-SVBPBHIXSA-N N-[(3,5-difluorophenyl)methyl]-N'-[(2S,11S)-2-[[[2-(4-fluorophenyl)acetyl]amino]methyl]-12-oxo-1-azatricyclo[6.4.1.04,13]trideca-4,6,8(13)-trien-11-yl]-2,2-dimethylpropanediamide Chemical compound FC=1C=C(CNC(C(C(=O)N[C@H]2CCC=3C=CC=C4C[C@H](N(C=34)C2=O)CNC(CC2=CC=C(C=C2)F)=O)(C)C)=O)C=C(C=1)F VEHTZQNYIWZNBK-SVBPBHIXSA-N 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- RWLPAIFXJQBFIL-UHFFFAOYSA-N n-(5-benzoyl-1-methyl-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl)-n'-[(3,5-difluorophenyl)methyl]-2-methylpropanediamide Chemical compound C1N(C(=O)C=2C=CC=CC=2)C2=CC=CC=C2N(C)C(=O)C1NC(=O)C(C)C(=O)NCC1=CC(F)=CC(F)=C1 RWLPAIFXJQBFIL-UHFFFAOYSA-N 0.000 claims 1
- DFWHHXKARVQVLV-UHFFFAOYSA-N n-(5-benzyl-1-methyl-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl)-n'-[(3,5-difluorophenyl)methyl]-2-methylpropanediamide Chemical compound C1N(CC=2C=CC=CC=2)C2=CC=CC=C2N(C)C(=O)C1NC(=O)C(C)C(=O)NCC1=CC(F)=CC(F)=C1 DFWHHXKARVQVLV-UHFFFAOYSA-N 0.000 claims 1
- BPAHSIQPJKUXIR-UHFFFAOYSA-N n-[(2,5-difluorophenyl)methyl]-2-methyl-n'-(5-methyl-6-oxo-7h-benzo[d][1]benzazepin-7-yl)propanediamide Chemical compound C12=CC=CC=C2C2=CC=CC=C2N(C)C(=O)C1NC(=O)C(C)C(=O)NCC1=CC(F)=CC=C1F BPAHSIQPJKUXIR-UHFFFAOYSA-N 0.000 claims 1
- FBBPCHXJVMRLFI-UHFFFAOYSA-N n-[(2-fluorophenyl)methyl]-2-methyl-n'-(5-methyl-6-oxo-7h-benzo[d][1]benzazepin-7-yl)propanediamide Chemical compound C12=CC=CC=C2C2=CC=CC=C2N(C)C(=O)C1NC(=O)C(C)C(=O)NCC1=CC=CC=C1F FBBPCHXJVMRLFI-UHFFFAOYSA-N 0.000 claims 1
- NEDPUDKYCQZPDL-UHFFFAOYSA-N n-[(3,5-difluorophenyl)methyl]-2,2-dimethyl-n'-(5-methyl-6-oxo-7h-benzo[d][1]benzazepin-7-yl)propanediamide Chemical compound O=C1N(C)C2=CC=CC=C2C2=CC=CC=C2C1NC(=O)C(C)(C)C(=O)NCC1=CC(F)=CC(F)=C1 NEDPUDKYCQZPDL-UHFFFAOYSA-N 0.000 claims 1
- PEVKDUMFGWFMNG-UHFFFAOYSA-N n-[(3,5-difluorophenyl)methyl]-2-ethyl-n'-(1-methyl-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl)propanediamide Chemical compound N1=C(C=2C=CC=CC=2)C2=CC=CC=C2N(C)C(=O)C1NC(=O)C(CC)C(=O)NCC1=CC(F)=CC(F)=C1 PEVKDUMFGWFMNG-UHFFFAOYSA-N 0.000 claims 1
- PPZAMCJTRDUVOG-UHFFFAOYSA-N n-[(3,5-difluorophenyl)methyl]-2-fluoro-n'-(5-methyl-6-oxo-7h-benzo[d][1]benzazepin-7-yl)propanediamide Chemical compound O=C1N(C)C2=CC=CC=C2C2=CC=CC=C2C1NC(=O)C(F)C(=O)NCC1=CC(F)=CC(F)=C1 PPZAMCJTRDUVOG-UHFFFAOYSA-N 0.000 claims 1
- IVPOPDLOBIZGEX-UHFFFAOYSA-N n-[(3,5-difluorophenyl)methyl]-n'-(1-methyl-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl)-2-propylpropanediamide Chemical compound N1=C(C=2C=CC=CC=2)C2=CC=CC=C2N(C)C(=O)C1NC(=O)C(CCC)C(=O)NCC1=CC(F)=CC(F)=C1 IVPOPDLOBIZGEX-UHFFFAOYSA-N 0.000 claims 1
- LRKNZXGABJUCOI-UHFFFAOYSA-N n-[(3,5-difluorophenyl)methyl]-n'-(5-methyl-6-oxo-7h-benzo[d][1]benzazepin-7-yl)-2-propan-2-ylpropanediamide Chemical compound C12=CC=CC=C2C2=CC=CC=C2N(C)C(=O)C1NC(=O)C(C(C)C)C(=O)NCC1=CC(F)=CC(F)=C1 LRKNZXGABJUCOI-UHFFFAOYSA-N 0.000 claims 1
- LJSQBHXWTBJLSW-UHFFFAOYSA-N n-[(3,5-difluorophenyl)methyl]-n'-(5-methyl-6-oxo-7h-benzo[d][1]benzazepin-7-yl)-2-propylpropanediamide Chemical compound C12=CC=CC=C2C2=CC=CC=C2N(C)C(=O)C1NC(=O)C(CCC)C(=O)NCC1=CC(F)=CC(F)=C1 LJSQBHXWTBJLSW-UHFFFAOYSA-N 0.000 claims 1
- NOOLHZQBHCVURF-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-2-methyl-n'-(5-methyl-6-oxo-7h-benzo[d][1]benzazepin-7-yl)propanediamide Chemical compound C12=CC=CC=C2C2=CC=CC=C2N(C)C(=O)C1NC(=O)C(C)C(=O)NCC1=CC=CC(F)=C1 NOOLHZQBHCVURF-UHFFFAOYSA-N 0.000 claims 1
- ORJXYBWSXQOSCA-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-methyl-n'-(1-methyl-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl)propanediamide Chemical compound N1=C(C=2C=CC=CC=2)C2=CC=CC=C2N(C)C(=O)C1NC(=O)C(C)C(=O)NCC1=CC=C(Cl)C=C1 ORJXYBWSXQOSCA-UHFFFAOYSA-N 0.000 claims 1
- AXCNCARXJIKPHA-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-methyl-n'-(5-methyl-6-oxo-7h-benzo[d][1]benzazepin-7-yl)propanediamide Chemical compound C12=CC=CC=C2C2=CC=CC=C2N(C)C(=O)C1NC(=O)C(C)C(=O)NCC1=CC=C(Cl)C=C1 AXCNCARXJIKPHA-UHFFFAOYSA-N 0.000 claims 1
- MJEYTKXDVDXMEQ-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-2-methyl-n'-(5-methyl-6-oxo-7h-benzo[d][1]benzazepin-7-yl)propanediamide Chemical compound C12=CC=CC=C2C2=CC=CC=C2N(C)C(=O)C1NC(=O)C(C)C(=O)NCC1=CC=C(F)C=C1 MJEYTKXDVDXMEQ-UHFFFAOYSA-N 0.000 claims 1
- YLGSLUBKNGFPOB-UHFFFAOYSA-N n-[5-(benzenesulfonyl)-1-methyl-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-n'-[(3,5-difluorophenyl)methyl]-2-methylpropanediamide Chemical compound C1N(S(=O)(=O)C=2C=CC=CC=2)C2=CC=CC=C2N(C)C(=O)C1NC(=O)C(C)C(=O)NCC1=CC(F)=CC(F)=C1 YLGSLUBKNGFPOB-UHFFFAOYSA-N 0.000 claims 1
- VRYUYXCAJGNNHF-UHFFFAOYSA-N n-benzyl-2-methyl-n'-(5-methyl-6-oxo-7h-benzo[d][1]benzazepin-7-yl)propanediamide Chemical compound C12=CC=CC=C2C2=CC=CC=C2N(C)C(=O)C1NC(=O)C(C)C(=O)NCC1=CC=CC=C1 VRYUYXCAJGNNHF-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 0 CN(C1)CC2=C1C=C*(*)C=C2 Chemical compound CN(C1)CC2=C1C=C*(*)C=C2 0.000 description 2
- KFBFSZIBRDCFHS-UHFFFAOYSA-N CCNC(Cc1ccc[s]1)=O Chemical compound CCNC(Cc1ccc[s]1)=O KFBFSZIBRDCFHS-UHFFFAOYSA-N 0.000 description 1
- SVYKKECYCPFKGB-UHFFFAOYSA-N CN(C)C1CCCCC1 Chemical compound CN(C)C1CCCCC1 SVYKKECYCPFKGB-UHFFFAOYSA-N 0.000 description 1
- ILABWDUPVPANGS-UHFFFAOYSA-N CN(CC1)C(C2)c3c1cccc3C2O Chemical compound CN(CC1)C(C2)c3c1cccc3C2O ILABWDUPVPANGS-UHFFFAOYSA-N 0.000 description 1
- XCWXFEJLAVJBRP-UHFFFAOYSA-N CN(CC1)CCN1S(C)(O)=O Chemical compound CN(CC1)CCN1S(C)(O)=O XCWXFEJLAVJBRP-UHFFFAOYSA-N 0.000 description 1
- XKVUYEYANWFIJX-UHFFFAOYSA-N Cc1n[nH]cc1 Chemical compound Cc1n[nH]cc1 XKVUYEYANWFIJX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C07C323/41—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (20)
1. Соединения общей формулы
представляет собой циклическое кольцо, выбранное из группы, состоящей из фенила, пиридинила, фуранила, бензо[b]тиофенила, тетрагидронафтила, инданила, 2,2-диметил-[1,3]диоксоланила или тетрагидрофуранила;
R1 и R1' являются одинаковыми или различными и представляют собой водород, низший алкил, галоген, бензил или низший алкенил;
(R2)1,2,3 независимо друг от друга представляют собой водород, гидрокси, галоген, низший алкил, низший алкокси или трифторметил;
R3 представляет собой
фенил или бензил, который является незамещенным или замещен одним или двумя заместителями, выбранными из группы, состоящей из галогена или циано, или представляет собой
низший алкил,
два атома водорода,
(СН2)1,2-S-низший алкил,
(СН2)1,2-циклоалкил,
(CH2)1,2-OH,
СН2ОСН2-фенил или группы
R4 представляет собой низший алкокси,
моно- или диалкиламино,
N(СН3)(СН2)1,2-С≡СН,
или представляет собой моно-, ди- или трициклическую группу,
незамещенную или замещенную R5-R10, и
где группы могут быть связаны с помощью -N(СН3)(СН2)0,1,2 с -С(O) группой в формуле IB, выбранные из группы, состоящей из
где (R5)1,2 независимо друг от друга представляет собой водород, галоген, низший алкил или -(СН2)1,2OH;
R6 представляет собой водород, галоген или низший алкокси;
R7 представляет собой водород или -СН2ОСН3;
R8 представляет собой водород или галоген;
R9 представляет собой водород, низший алкокси, низший алкил или амино;
(R10)1,2,3 независимо друг от друга представляет собой водород, низший алкил, низший алкокси, низший циклоалкил, галоген, гидрокси, =O, амино, нитро, -CH2CN, -ОСН2С6Н5,
где Х представляет собой -СН2, -S(O)2 или -С(О)-;
R11 представляет собой водород или низший алкил;
R12 представляет собой водород или галоген;
R14 представляет собой водород, низший алкил, -(СН2)2OH или -(CH2)2CN;
и их фармацевтически приемлемые кислотные аддитивные соли.
2. Соединения общей формулы
где R1 и R1' являются одинаковыми или различными и представляют собой водород, низший алкил, галоген, бензил или низший алкенил;
(R2)1,2,3 независимо друг от друга представляет собой водород, галоген, низший алкил, низший алкокси или трифторметил;
R3 представляет собой фенил или бензил, которые являются незамещенными или замещены одним или двумя заместителями, выбранными из группы, состоящей из галогена или циано, или представляет собой
низший алкил,
два атома водорода,
(СН2)1,2-S-низший алкил,
(СН2)1,2-циклоалкил,
(CH2)1,2-OH,
СН2OCH2-фенил или группы
R4 представляет собой низший алкокси,
моно- или диалкиламино,
N(СН3)(СН2)1,2-С≡СН,
или представляет собой моно-, ди- или трициклическую группу,
незамещенную или замещенную R5-R10, и
где группы могут быть связаны с помощью -N(СН3)(СН2)0,1,2 с -С(O)-группой в формуле IB, выбранные из группы, состоящей из
где (R5)1,2 независимо друг от друга представляет собой водород, галоген, низший алкил или -(CH2)1,2OH;
R6 представляет собой водород, галоген или низший алкокси;
R7 представляет собой водород или -СН2ОСН3;
R8 представляет собой водород или галоген;
R9 представляет собой водород, низший алкокси, низший алкил или амино;
(R10)1,2,3 независимо друг от друга представляет собой водород, низший алкил, низший алкокси, низший циклоалкил, галоген, гидрокси, =O, амино, нитро, -CH2CN, -ОСН2С6Н5,
где Х представляет собой -СН2, -S(O)2 или -С(O)-;
R11 представляет собой водород или низший алкил;
R12 представляет собой водород или галоген;
и их фармацевтически приемлемые кислотные аддитивные соли.
3. Соединения формулы IA по п.2.
5. Соединения формулы IA по п.4, где соединения представляют собой
N-(3,5-дифторбензил)-2-метил-N'-(5-метил-6-оксо-6,7-дигидро-5Н-дибензо[b,d]азепин-7-ил)-малонамид,
N-(3,5-дифторбензил)-2-фтор-2-метил-N'-(5-метил-6-оксо-6,7-дигидро-5Н-дибензо[b,d]азепин-7-ил)-малонамид,
N-(3,5-дифторбензил)-2-изопропил-N'-(5-метил-6-оксо-6,7-дигидро-5Н-дибензо[b,d]азепин-7-ил)-малонамид,
N-(3,5-дифторбензил)-2-этил-N'-(5-метил-6-оксо-6,7-гидро-5Н-дибензо[b,d]азепин-7-ил)-малонамид,
N-(3,5-дифторбензил)-2-фтор-N'-(5-метил-6-оксо-6,7-дигидро-5Н-дибензо[b,d]азепин-7-ил)-малонамид,
N-(3,5-дифторбензил)-2,2-диметил-N'-(5-метил-6-оксо-6,7-дигидро-5Н-дибензо[b,d]азепин-7-ил)-малонамид,
N-(3,5-дифторбензил)-N'-(5-метил-6-оксо-6,7-дигидро-5Н-дибензо[b,d]азепин-7-ил)-2-пропил-малонамид,
N-бензил-2-метил-N'-(5-метил-6-оксо-6,7-дигидро-5Н-дибензо[b,d]азепин-7-ил)-малонамид,
N-(4-фторбензил)-2-метил-N'-(5-метил-6-оксо-6,7-дигидро-5Н-дибензо[b,d]азепин-7-ил)-малонамид,
N-(4-хлорбензил)-2-метил-N'-(5-метил-6-оксо-6,7-дигидро-5Н-дибензо[b,d]азепин-7-ил)-малонамид,
N-(3-фторбензил)-2-метил-N'-(5-метил-6-оксо-6,7-дигидро-5Н-дибензо[b,d]азепин-7-ил)-малонамид,
N-(2,5-дифторбензил)-2-метил-N'-(5-метил-6-оксо-6,7-дигидро-5Н-дибензо[b,d]азепин-7-ил)-малонамид,
2-метил-N-(5-метил-6-оксо-6,7-дигидро-5Н-дибензо[b,d]азепин-7-ил)-N'-(2,3,5-трифторбензил)-малонамид,
N-(2-фторбензил)-2-метил-N'-(5-метил-6-оксо-6,7-дигидро-5Н-дибензо[b,d]азепин-7-ил)-малонамид,
N-(2-хлорбензил)-2-метил-N'-(5-метил-6-оксо-6,7-дигидро-5Н-дибензо[b,d]азепин-7-ил)-малонамид или
N-(3-хлорбензил)-2-метил-N'-(5-метил-6-оксо-6,7-дигидро-5Н-дибензо[b,d]азепин-7-ил)-малонамид.
7. Соединения формулы IA по п.6, где соединения представляют собой
N-фуран-2-илметил-2-метил-N'-(5-метил-6-оксо-6,7-дигидро-5Н-дибензо[b,d]азепин-7-ил)-малонамид,
N-бензо[b]тиофен-3-илметил-2-метил-N'-(5-метил-6-оксо-6,7-дигидро-5Н-дибензо[b,d]азепин-7-ил)-малонамид или
N-(4,6-дифториндан-1-ил)-2-метил-N'-(5-метил-6-оксо-6,7-дигидро-5Н-дибензо[b,d]азепин-7-ил)-малонамид.
9. Соединения формулы IA по п.8, где соединения представляют собой
(N-(3,5-дифторбензил)-2-метил-N'-(1-метил-2-оксо-5-фенил-2,3-дигидро-1Н-бензо[e][1,4]диазепин-3-ил)-малонамид,
N-(3,5-дифторбензил)-2-фтор-2-метил-N'-(1-метил-2-оксо-5-фенил-2,3-дигидро-1Н-бензо[e][1,4]диазепин-3-ил)-малонамид,
N(3,5-дифторбензил)-N'-(1-метил-2-оксо-5-фенил-2,3-дигидро-1Н-бензо[e][1,4]диазепин-3-ил)-2-пропил-малонамид,
N-(3,5-дифторбензил)-2-этил-N'-(1-метил-2-оксо-5-фенил-2,3-дигидро-1Н-бензо[e][1,4]диазепин-3-ил)-малонамид или
N-(4-хлорбензил)-2-метил-N'-(1-метил-2-оксо-5-фенил-2,3-дигидро-1Н-бензо[e][1,4]диазепин-3-ил)-малонамид.
11. Соединения формулы IA по п.10, где соединения представляют собой
N-(5-бензил-1-метил-2-оксо-2,3,4,5-тетрагидро-1Н-бензо[b][1,4]диазепин-3-ил)-N'-(3,5-дифторбензил)-2-метил-малонамид,
N-(5-бензолсульфонил-1-метил-2-оксо-2,3,4,5-тетрагидро-1Н-бензо[b][1,4]диазепин-3-ил)-N'-(3,5-дифторбензил)-2-метил-малонамид или
N-(5-бензоил-1-метил-2-оксо-2,3,4,5-тетрагидро-1Н-бензо[b][1,4]диазепин-3-ил)-N'-(3,5-дифторбензил)-2-метил-малонамид.
13. Соединения формулы IA по п.12, где соединения представляют собой
(2S-цис)-N-(3,5-дифторбензил)-2-метил-N'-{4-оксо-2-[(2-тиофен-2-ил-ацетиламино)-(2R,S)-метил]-1,2,4,5,6,7-гексагидроазепино[3,2,1-hi]индол-5-ил}-малонамид или
(2S-цис)-N-(3,5-дифторбензил)-N'-(2-{[2-(4-фторфенил)ацетиламино]метил}-4-оксо-1,2,4,5,6,7-гексагидроазепино[3,2,1-hi]индол-5-ил)-2,2-диметил-малонамид.
14. Соединения формулы IB по п.1 или 2.
15. Соединения формул IA или IB по п.1 или 2, где по крайней мере один из (R2)1,2,3 представляет собой фтор.
16. Способ получения соединения формул IA или IB по пп.1-15, где способ включает
а) реакцию соединения формулы
с соединением формулы
с получением соединения формулы
где заместители являются такими, как определено в п.1, или
б) реакцию соединения формулы
с соединением формулы
с получением соединения формулы
где заместители являются такими, как определено в п.1,
в) реакцию соединения формулы
с соединением формулы
с получением соединения формулы
где заместители являются такими, как определено в п.1, и
при необходимости, превращение полученных соединений в фармацевтически приемлемые кислотные аддитивные соли.
17. Соединение по любому из пп.1-15, полученное способом по п.16 или эквивалентным способом.
18. Лекарственное средство, содержащее одно или несколько соединений по любому из пп.1-15 и фармацевтически приемлемые эксципиенты.
19. Лекарственное средство по п.18 для лечения болезни Альцгеймера.
20. Применение соединения по любому одному из пп.1-15 для изготовления лекарственных средств для лечения болезни Альцгеймера.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03002190 | 2003-02-04 | ||
EP03002190.1 | 2003-02-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2005127666A true RU2005127666A (ru) | 2006-04-27 |
RU2330849C2 RU2330849C2 (ru) | 2008-08-10 |
Family
ID=32842686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2005127666/04A RU2330849C2 (ru) | 2003-02-04 | 2004-01-27 | МАЛОНАМИДНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ γ-СЕКРЕТАЗЫ |
Country Status (23)
Country | Link |
---|---|
US (1) | US7375099B2 (ru) |
EP (1) | EP1592684B1 (ru) |
JP (1) | JP4662914B2 (ru) |
KR (1) | KR100810810B1 (ru) |
CN (1) | CN100480248C (ru) |
AR (1) | AR042996A1 (ru) |
AT (1) | ATE402934T1 (ru) |
BR (1) | BRPI0407262A (ru) |
CA (1) | CA2514267C (ru) |
CL (1) | CL2004000174A1 (ru) |
CO (1) | CO5580761A2 (ru) |
DE (1) | DE602004015415D1 (ru) |
ES (1) | ES2311795T3 (ru) |
HR (1) | HRP20050663A2 (ru) |
IL (1) | IL169691A (ru) |
MX (1) | MXPA05008172A (ru) |
NO (1) | NO20053627L (ru) |
NZ (1) | NZ541324A (ru) |
PL (1) | PL378405A1 (ru) |
RU (1) | RU2330849C2 (ru) |
TW (1) | TWI293070B (ru) |
WO (1) | WO2004069826A1 (ru) |
ZA (1) | ZA200506212B (ru) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
MXPA06002562A (es) * | 2003-09-09 | 2006-06-20 | Hoffmann La Roche | Derivados de malonamida que bloquean la actividad de la gamma-secretasa. |
HUE025548T2 (en) | 2003-10-06 | 2016-02-29 | Hoffmann La Roche | Substituted dibenzo-azepine and benzodiazepine derivatives useful as gamma-secretase inhibitors |
US7211573B2 (en) * | 2004-12-08 | 2007-05-01 | Hoffmann-La Roche Inc. | Malonamide derivatives |
WO2006115845A1 (en) | 2005-04-20 | 2006-11-02 | Merck & Co., Inc. | Benzothiophene derivatives |
AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
ES2398531T3 (es) | 2006-03-27 | 2013-03-20 | F. Hoffmann-La Roche Ag | Derivados de malonamida como inhibidores de gamma secretasa |
EP2069317A2 (en) | 2006-09-20 | 2009-06-17 | F. Hoffmann-Roche AG | 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
WO2008065141A1 (en) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
KR101150574B1 (ko) * | 2007-02-02 | 2012-05-30 | 에프. 호프만-라 로슈 아게 | 6-옥소-6,7-다이하이드로-5h-다이벤조[b,d]아제핀-7-일 유도체 |
EP2481408A3 (en) | 2007-03-01 | 2013-01-09 | Probiodrug AG | New use of glutaminyl cyclase inhibitors |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
EP2865670B1 (en) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
US7579464B2 (en) * | 2007-05-25 | 2009-08-25 | Hoffmann-La Roche Inc. | Process for preparation of enantiomerically pure compounds |
CN101801930B (zh) | 2007-09-14 | 2013-01-30 | 奥梅-杨森制药有限公司 | 1,3-二取代的-4-苯基-1h-吡啶-2-酮 |
AU2008297876B2 (en) | 2007-09-14 | 2011-07-07 | Addex Pharma S.A. | 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
BRPI0816767B8 (pt) | 2007-09-14 | 2021-05-25 | Addex Pharmaceuticals Sa | composto 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridi¬nil-2'-onas 1',3'-dissubstituídas, composição farmacêutica e uso dos mesmos |
ES2637794T3 (es) | 2007-11-14 | 2017-10-17 | Janssen Pharmaceuticals, Inc. | Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2 |
AU2009289784B2 (en) | 2008-09-02 | 2012-03-22 | Addex Pharma S.A. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
WO2010043396A1 (en) | 2008-10-16 | 2010-04-22 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
WO2010060589A1 (en) | 2008-11-28 | 2010-06-03 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
US8946205B2 (en) | 2009-05-12 | 2015-02-03 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
MY161325A (en) | 2009-05-12 | 2017-04-14 | Janssen Pharmaceuticals Inc | 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
US8486940B2 (en) | 2009-09-11 | 2013-07-16 | Probiodrug Ag | Inhibitors |
US20110190269A1 (en) * | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
EP2545047B9 (en) | 2010-03-10 | 2015-06-10 | Probiodrug AG | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
CN103261195B (zh) | 2010-11-08 | 2015-09-02 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
AU2011328203B2 (en) | 2010-11-08 | 2015-03-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
PL2649069T3 (pl) | 2010-11-08 | 2016-01-29 | Janssen Pharmaceuticals Inc | Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2 |
JP6050264B2 (ja) | 2011-03-16 | 2016-12-21 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
TWI530489B (zh) | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | 雙(氟烷基)-1,4-苯二氮呯酮化合物 |
JO3148B1 (ar) | 2011-07-27 | 2017-09-20 | Lilly Co Eli | مركب مثبط لإشارات مسار notch |
WO2014035707A1 (en) * | 2012-08-25 | 2014-03-06 | The Johns Hopkins University | Gapdh cascade inhibitor compounds and methods of use and treatment of stress induced disorders including mental illness |
US9273075B2 (en) | 2012-09-21 | 2016-03-01 | Bristol-Myers Squibb Company | Prodrugs of 1,4-benzodiazepinone compounds |
CN104854097A (zh) | 2012-09-21 | 2015-08-19 | 百时美施贵宝公司 | N-取代的二(氟烷基)-1,4-苯并二氮杂*酮化合物 |
EP2897960B1 (en) | 2012-09-21 | 2016-08-03 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds as notch inhibitors |
CN104854094A (zh) | 2012-09-21 | 2015-08-19 | 百时美施贵宝公司 | 氟烷基二苯并二氮杂*酮化合物 |
WO2014047397A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch|inhibitors |
TWI614238B (zh) | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | 雙(氟烷基)-1,4-苯并二氮呯酮化合物及其前藥 |
CN104822677A (zh) | 2012-09-21 | 2015-08-05 | 百时美施贵宝公司 | 氟烷基-1,4-苯并二氮杂*酮化合物 |
WO2014047369A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Substituted 1,5-benzodiazepinone compounds |
US9242941B2 (en) | 2012-09-21 | 2016-01-26 | Bristol-Myers Squibb Company | Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds |
JP2016515625A (ja) | 2013-04-04 | 2016-05-30 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 増殖性疾患を治療するための併用療法 |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
UA121965C2 (uk) | 2014-01-21 | 2020-08-25 | Янссен Фармацевтика Нв | Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування |
KR102461134B1 (ko) | 2014-01-21 | 2022-10-28 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993003011A1 (en) * | 1991-08-08 | 1993-02-18 | Yamanouchi Pharmaceutical Co., Ltd. | Urea derivative |
WO2001027108A1 (en) * | 1999-10-08 | 2001-04-19 | Bristol-Myers Squibb Pharma Company | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
JP2003535046A (ja) * | 2000-04-03 | 2003-11-25 | デュポン ファーマシューティカルズ カンパニー | Aβタンパク質産生の阻害剤としての環状ラクタム |
CA2404273A1 (en) | 2000-04-11 | 2001-10-18 | Bristol-Myers Squibb Pharma Company | Substituted lactams as inhibitors of a.beta. protein production |
MXPA06002562A (es) * | 2003-09-09 | 2006-06-20 | Hoffmann La Roche | Derivados de malonamida que bloquean la actividad de la gamma-secretasa. |
-
2004
- 2004-01-27 WO PCT/EP2004/000674 patent/WO2004069826A1/en active IP Right Grant
- 2004-01-27 RU RU2005127666/04A patent/RU2330849C2/ru not_active IP Right Cessation
- 2004-01-27 CA CA2514267A patent/CA2514267C/en not_active Expired - Fee Related
- 2004-01-27 CN CNB2004800033052A patent/CN100480248C/zh not_active Expired - Fee Related
- 2004-01-27 BR BR0407262-6A patent/BRPI0407262A/pt not_active IP Right Cessation
- 2004-01-27 MX MXPA05008172A patent/MXPA05008172A/es active IP Right Grant
- 2004-01-27 EP EP04705404A patent/EP1592684B1/en not_active Expired - Lifetime
- 2004-01-27 NZ NZ541324A patent/NZ541324A/en unknown
- 2004-01-27 PL PL378405A patent/PL378405A1/pl not_active Application Discontinuation
- 2004-01-27 KR KR1020057014244A patent/KR100810810B1/ko not_active IP Right Cessation
- 2004-01-27 DE DE602004015415T patent/DE602004015415D1/de not_active Expired - Lifetime
- 2004-01-27 ES ES04705404T patent/ES2311795T3/es not_active Expired - Lifetime
- 2004-01-27 AT AT04705404T patent/ATE402934T1/de active
- 2004-01-27 JP JP2006500017A patent/JP4662914B2/ja not_active Expired - Fee Related
- 2004-01-29 US US10/767,784 patent/US7375099B2/en not_active Expired - Fee Related
- 2004-01-30 TW TW093102218A patent/TWI293070B/zh active
- 2004-02-02 AR ARP040100306A patent/AR042996A1/es not_active Application Discontinuation
- 2004-02-02 CL CL200400174A patent/CL2004000174A1/es unknown
-
2005
- 2005-07-14 IL IL169691A patent/IL169691A/en not_active IP Right Cessation
- 2005-07-21 HR HR20050663A patent/HRP20050663A2/xx not_active Application Discontinuation
- 2005-07-25 CO CO05072813A patent/CO5580761A2/es not_active Application Discontinuation
- 2005-07-26 NO NO20053627A patent/NO20053627L/no not_active Application Discontinuation
- 2005-08-03 ZA ZA200506212A patent/ZA200506212B/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20050105452A (ko) | 2005-11-04 |
NO20053627L (no) | 2005-08-10 |
CN100480248C (zh) | 2009-04-22 |
AR042996A1 (es) | 2005-07-13 |
NZ541324A (en) | 2008-10-31 |
US7375099B2 (en) | 2008-05-20 |
RU2330849C2 (ru) | 2008-08-10 |
JP2006516556A (ja) | 2006-07-06 |
WO2004069826A1 (en) | 2004-08-19 |
CN1745076A (zh) | 2006-03-08 |
JP4662914B2 (ja) | 2011-03-30 |
ZA200506212B (en) | 2006-05-31 |
TWI293070B (en) | 2008-02-01 |
ATE402934T1 (de) | 2008-08-15 |
CO5580761A2 (es) | 2005-11-30 |
IL169691A0 (en) | 2007-07-04 |
BRPI0407262A (pt) | 2006-01-31 |
EP1592684B1 (en) | 2008-07-30 |
CA2514267C (en) | 2011-05-17 |
ES2311795T3 (es) | 2009-02-16 |
AU2004210036A1 (en) | 2004-08-19 |
KR100810810B1 (ko) | 2008-03-06 |
PL378405A1 (pl) | 2006-04-03 |
TW200423928A (en) | 2004-11-16 |
EP1592684A1 (en) | 2005-11-09 |
DE602004015415D1 (de) | 2008-09-11 |
HRP20050663A2 (en) | 2006-12-31 |
MXPA05008172A (es) | 2005-10-05 |
IL169691A (en) | 2011-03-31 |
CA2514267A1 (en) | 2004-08-19 |
US20040220222A1 (en) | 2004-11-04 |
CL2004000174A1 (es) | 2005-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2005127666A (ru) | Малонамидные производные в качестве ингибиторов гамма-секретазы | |
RU2394031C2 (ru) | Соли четвертичного аммония в качестве антагонистов м3 | |
RU98110007A (ru) | Конденсированные тропановые производные в качестве ингибиторов обратного захвата нейромедиаторов | |
RU2007149327A (ru) | Гидантоиновые соединения | |
TWI224102B (en) | Serotonergic agents | |
RU2005133994A (ru) | Оксимные производные и их применение в качестве фармацевтически активных агентов | |
RU2003134544A (ru) | Амиды антраниловой кислоты, способы их получения, их применение в качестве антиаритмических средств, а также содержащие их фармацевтические композиции | |
RU2007140737A (ru) | Пиразолы | |
RU2006116887A (ru) | Производные n-[гетероарил(пиперидин-2-ил)метил]бензамида, способ получения указанных соединений и их применение в терапии | |
RU2007101685A (ru) | Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения | |
RU2008123376A (ru) | Производные 4-(4-алкокси-3-гидроксифенил)-2-пирролидона в качестве ингибиторов pde-4 для лечения неврологических синдромов | |
JP2005527579A5 (ru) | ||
JP2005511698A5 (ru) | ||
RU2004105260A (ru) | Производные 8-метокси(1,2,4)триазоло(1,5-а)пиридина и их применение в качестве лигандов рецептора аденозина | |
RU2001133004A (ru) | Применение селективных антагонистов альфа1b-адренергического рецептора для улучшения состояния при сексуальной дисфункции | |
RU2007121219A (ru) | Диазациклоалканы как агонисты окситоцина | |
RU2007125661A (ru) | Арилоксиэтиламиновые и фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофимина-d2 и ингибирования повторного поглощения серотонина | |
RU2005107589A (ru) | Антидепрессанты-азагетероциклилметильные производные конденсированных с гетероциклами бензодиоксанов | |
RU2440342C2 (ru) | МАЛОНАМИДНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ γ-СЕКРЕТАЗЫ | |
RU96121937A (ru) | Производные тропан-2-альдоксима в качестве ингибиторов обратного захвата нейротрансмиттеров | |
RU2002133458A (ru) | Соединения пиперазина и пиперидина | |
JP2006504738A5 (ru) | ||
RU2005129550A (ru) | Антагонисты рецептора ccr-3 | |
RU2006113942A (ru) | Производные бензимидазолона и хиназолина как ангонисты orl-рецепторов человека | |
RU2004131651A (ru) | Фталимидопроизводные в качестве ингибиторов моноаминооксидазы в |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20090128 |